All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, Sobi, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
NICE recommends acalabrutinib combinations for MCL and CLL
On August 6, 2026, the National Institute for Health and Care Excellence (NICE) announced the recommendation of acalabrutinib combinations for the treatment of newly diagnosed mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).1
Acalabrutinib was recommended in combination with bendamustine + rituximab for the treatment of patients with MCL, supported by results from the phase III ECHO trial (NCT02972840).1,2 The addition of acalabrutinib to bendamustine + rituximab resulted in a median progression-free survival of 72.5 months vs 47.8 months with bendamustine + rituximab alone (p = 0.002). Safety outcomes were comparable between arms, with similar cumulative rates of Grade ≥3 adverse events (AEs).2
Acalabrutinib was also recommended for the treatment of patients with CLL, in combination with venetoclax, supported by results from the phase III AMPLIFY trial (NCT03836261).1,3 The risk of disease progression or death was reduced with acalabrutinib + venetoclax vs chemoimmunotherapy (hazard ratio, 0.65; 95% confidence interval, 0.49–0.87; p = 0.004).3 Grade ≥3 AEs were reported in 53.6% and 60.6% of patients in the acalabrutinib + venetoclax and chemoimmunotherapy arms, respectively.3
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
